Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

169864

	registered interest
	date	11/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Raloxifene
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he plans to take to ensure the routine availability of raloxifene to reduce the risk of breast cancer developing in high-risk women.
	tabling member constituency	Coatbridge, Chryston and Bellshill
	tabling member printed	Mr Tom Clarke
	uin	218384
	answer	answer is ministerial correction date of answer 17/12/2014 answer text <p> </p><p /> <p>I refer the hon. Member to the Answer I gave the hon. Member for Bolton South East (<a href="http://www.parliament.uk/biographies/commons/yasmin-qureshi/3924" target="_blank">Yasmin Qureshi</a>) on 19 November 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-10/213936/" target="_blank">213936</a>.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/12/2014 17:27:43 answering member 4020 label Biography information for George Freeman
	tabling member	583 label Biography information for Mr Tom Clarke

167784

	registered interest
	date	03/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bladder Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the extent of availability of the cancer drug Immunocyst used in bacillus Calmette-Guerin (BCG) cancer treatment.
	tabling member constituency	Dudley North
	tabling member printed	Ian Austin
	uin	217119
	answer	answer is ministerial correction date of answer 10/12/2014 answer text <p><strong> </strong></p><p /> <p> </p><p /> <p> </p><p /> <p>The supplier of ImmuCyst, Alliance Pharmaceuticals, has experienced manufacturing problems which have affected its supply on a worldwide basis. The product has been unavailable since summer 2012. However the problems are in the process of being resolved and it is expected to be available in 2015.</p><p /> <p> </p><p /> <p>The Department and the Medicines and Healthcare products Regulatory Agency are working closely with Alliance Pharmaceuticals and the supplier of alternative bacillus Calmette-Guerin (BCG) bladder instillations to help ensure that supplies are available for United Kingdom patients.</p><p /> <p> </p><p /> <p><strong> </strong></p><p /> <p> </p><p /> <p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 217118 question first answered 10/12/2014 16:48:27 answering member 4020 label Biography information for George Freeman
	tabling member	1511 label Biography information for Lord Austin of Dudley

167783

	registered interest
	date	03/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bladder Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department has taken to secure a supply of the cancer drug Immunocyst to be used in bacillus Calmette-Guerin (BCG) cancer treatment.
	tabling member constituency	Dudley North
	tabling member printed	Ian Austin
	uin	217118
	answer	answer is ministerial correction date of answer 10/12/2014 answer text <p><strong> </strong></p><p /> <p> </p><p /> <p> </p><p /> <p>The supplier of ImmuCyst, Alliance Pharmaceuticals, has experienced manufacturing problems which have affected its supply on a worldwide basis. The product has been unavailable since summer 2012. However the problems are in the process of being resolved and it is expected to be available in 2015.</p><p /> <p> </p><p /> <p>The Department and the Medicines and Healthcare products Regulatory Agency are working closely with Alliance Pharmaceuticals and the supplier of alternative bacillus Calmette-Guerin (BCG) bladder instillations to help ensure that supplies are available for United Kingdom patients.</p><p /> <p> </p><p /> <p><strong> </strong></p><p /> <p> </p><p /> <p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 217119 question first answered 10/12/2014 16:48:26 answering member 4020 label Biography information for George Freeman
	tabling member	1511 label Biography information for Lord Austin of Dudley

169541

	registered interest
	date	10/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions he has had with bodies that represent pharmacists, GPs and other stakeholders on prescription direction; and if he will make a statement.
	tabling member constituency	Watford
	tabling member printed	Richard Harrington
	uin	218212
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>All patients are free to choose whichever pharmacy they wish to receive their dispensed medicines and other National Health Service pharmaceutical services. We deprecate any action which seeks unduly to influence patients towards, or away from, choosing a particular pharmacy.</p><p> </p><p> </p><p> </p><p>The Pharmaceutical Services Negotiating Committee, Pharmacy Voice and the British Medical Association issued a joint statement in October 2013 calling on general practitioners to avoid activities which are against good practice. A copy can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://psnc.org.uk/contract-it/pharmacy-regulation/direction-of-prescriptions/" target="_blank">http://psnc.org.uk/contract-it/pharmacy-regulation/direction-of-prescriptions/</a></p><p> </p><p> </p><p> </p><p>Officials at the Department have met pharmacists’ representatives to discuss the direction of prescriptions on several occasions to hear their concerns. NHS England is currently reviewing the evidence and is meeting pharmacists’ and medical representatives this month to consider the position and what further action may be appropriate.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2014 17:20:34 answering member 4020 label Biography information for George Freeman
	tabling member	4068 label Biography information for Lord Harrington of Watford

168043

	registered interest
	date	04/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Multiple Sclerosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the compatibility of the availability of sativex through the NHS with the classification of cannabis as a Schedule One substance.
	tabling member constituency	Lewes
	tabling member printed	Norman Baker
	uin	217173
	answer	answer is ministerial correction date of answer 09/12/2014 answer text <p>Cannabis is a Class B drug under the Misuse of Drugs Act 1971 and is listed in Schedule 1 under the Misuse of Drugs Regulations 2001. Cannabis in its raw form is not authorised as a medicinal product in the United Kingdom and no assessment has been made by the Government of its potential medicinal benefits.</p><p> </p><p> </p><p> </p><p>Sativex is the first cannabis-based medicine (oral spray) to be recognised by the Medicines and Healthcare products Regulatory Agency to have medicinal properties and is placed in Part I of Schedule 4 to the Misuse of Drugs Regulations 2001. This distinguishes it from cannabis in its raw form which continues to remain a Class B and Schedule 1 controlled drug under UK legislation. A person can lawfully possess Sativex under a prescription issued by a qualified healthcare professional.</p><p> </p><p> </p><p> </p><p>However, Sativex remains a Class B drug under the Misuse of Drugs Act 1971 Act and Class B drug offences, including unlawful possession, supply, possession with intent to supply etc, continue to apply to Sativex.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/12/2014 16:04:06 answering member 4020 label Biography information for George Freeman
	tabling member	28 label Biography information for Norman Baker

169854

	registered interest
	date	11/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmaceutical Price Regulation Scheme: Scotland
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, on what basis the Pharmaceutical Price Regulation Scheme rebate allocation has been calculated for Scotland.
	tabling member constituency	Edinburgh West
	tabling member printed	Mike Crockart
	uin	218370
	answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>Companies pay all Pharmaceutical Price Regulation Scheme payments to the Department of Health in England. The total United Kingdom payments will be allocated to each of the four UK countries in a fair way and the estimated payments for England have been included within the NHS England budget. The method for apportioning 2014-15 payments will be based on primary care data for spend on licensed branded medicines, as the most consistent data set available across the UK. Income will be apportioned using prescribing data for the same period as the income relates, on a quarterly basis.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 17:23:49 answering member 4020 label Biography information for George Freeman
	tabling member	3967 label Biography information for Mike Crockart

170440

	registered interest
	date	15/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect of re-evaluating the Cancer Drugs Fund list on breast cancer patients.
	tabling member constituency	Brigg and Goole
	tabling member printed	Andrew Percy
	uin	218764
	answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>I refer my hon. Friend to the Answer I gave the hon. Member for Bromley and Chislehurst (Robert Neill) on 16 December 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-12-09/217858/" target="_blank">217858</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 17:34:50 answering member 4020 label Biography information for George Freeman
	tabling member	3939 label Biography information for Andrew Percy

170453

	registered interest
	date	15/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescription Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will develop a strategy and workplan with targets for increasing the use of off-label medicines.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	218686
	answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Crawley (Henry Smith) on 24 November 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-17/214424/" target="_blank">214424</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 15:49:03 answering member 4020 label Biography information for George Freeman
	tabling member	4243 label Biography information for Dan Jarvis

168957

	registered interest
	date	09/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bladder Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that OncoTICE is readily available to treat patients who have cancer of the bladder.
	tabling member constituency	Kilmarnock and Loudoun
	tabling member printed	Cathy Jamieson
	uin	217880
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Liverpool Wavertree (Luciana Berger) on 1 December 2014 to Questions <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-26/216172/" target="_blank">216172, 216173 and 216174</a> concerning shortages of Bacillus Calmette-Guérin bladder instillations, one of which is OncoTICE.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 217879 question first answered 15/12/2014 17:05:33 answering member 4020 label Biography information for George Freeman
	tabling member	4011 label Biography information for Cathy Jamieson

168959

	registered interest
	date	09/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Bladder Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many patients have had delays in treatment for cancer of the bladder as a result of shortages of the drug OncoTICE in each of the last two years.
	tabling member constituency	Kilmarnock and Loudoun
	tabling member printed	Cathy Jamieson
	uin	217879
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Liverpool Wavertree (Luciana Berger) on 1 December 2014 to Questions <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-26/216172/" target="_blank">216172, 216173 and 216174</a> concerning shortages of Bacillus Calmette-Guérin bladder instillations, one of which is OncoTICE.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 217880 question first answered 15/12/2014 17:05:33 answering member 4020 label Biography information for George Freeman
	tabling member	4011 label Biography information for Cathy Jamieson